Log in

TIGENIX/S Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
-0.09 (-0.68 %)
(As of 10/20/2020 12:00 AM ET)
Today's Range
Now: $13.19
50-Day Range N/A
52-Week Range
Now: $13.19
Volume73,171 shs
Average Volume124,317 shs
Market Capitalization$674.67 million
P/E RatioN/A
Dividend YieldN/A
TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases. The company's lead product candidate is the Cx601, which completed Phase III clinical trials for the treatment of complex perianal fistulas in patients suffering from Crohn's disease. It also engages in developing Cx611, a clinical stage product candidate from its expanded adipose-derived stem cell-based (eASC-based) technology platform, which completed a Phase I study in sepsis and a Phase Ib/IIa trial for the treatment of refractory rheumatoid arthritis; and Cx621, which has completed a Phase I trial for the treatment of intra lymphatic administration of allogeneic eASCs. It is also developing AlloCSC-01, a product candidate based on the CSC-based platform, which has completed a Phase I/II study in acute myocardial infarction. The company has operations in Belgium, Spain, and the United States. TiGenix NV was founded in 2000 and is headquartered in Leuven, Belgium. As of July 3, 2018, TiGenix NV operates as a subsidiary of Takeda Pharmaceutical Company Limited.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars

Industry, Sector and Symbol

Industry Fire, marine, & casualty insurance
Current SymbolNASDAQ:TIG



Sales & Book Value

Annual SalesN/A



Market Cap$674.67 million
Next Earnings DateN/A
OptionableNot Optionable

Receive TIG News and Ratings via Email

Sign-up to receive the latest news and ratings for TIG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

TIGENIX/S (NASDAQ:TIG) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of TIGENIX/S?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TIGENIX/S in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for TIGENIX/S

What price target have analysts set for TIG?

4 brokers have issued 1-year target prices for TIGENIX/S's stock. Their forecasts range from $19.00 to $21.00. On average, they expect TIGENIX/S's share price to reach $20.00 in the next twelve months. This suggests a possible upside of 51.6% from the stock's current price.
View analysts' price targets for TIGENIX/S

Who are some of TIGENIX/S's key competitors?

What other stocks do shareholders of TIGENIX/S own?

Who are TIGENIX/S's key executives?

TIGENIX/S's management team includes the following people:
  • Dr. Claudia D'Augusta, Chief Financial Officer and Compliance Officer (Age 48)
  • Mr. Wilfried Dalemans, Chief Technical Officer (Age 60)
  • Claudia Jiménez, Sr. Director of Investor Relations & Communications
  • An Moonen, Gen. Counsel and Company Sec.
  • Dr. Marie Paule Richard, Chief Medical Officer (Age 63)


(TIG) raised $150 million in an initial public offering (IPO) on Thursday, July 16th 2020. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, Evercore ISI and William Blair served as the underwriters for the IPO and JMP Securities was co-manager.

What is TIGENIX/S's stock symbol?

TIGENIX/S trades on the NASDAQ under the ticker symbol "TIG."

When does the company's lock-up period expire?

TIGENIX/S's lock-up period expires on Tuesday, January 12th. TIGENIX/S had issued 10,714,286 shares in its initial public offering on July 16th. The total size of the offering was $160,714,290 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

What is TIGENIX/S's stock price today?

One share of TIG stock can currently be purchased for approximately $13.19.

How big of a company is TIGENIX/S?

TIGENIX/S has a market capitalization of $674.67 million.

What is TIGENIX/S's official website?

The official website for TIGENIX/S is www.trean.com.

How can I contact TIGENIX/S?

TIGENIX/S's mailing address is 150 LAKE STREET WEST, WAYZATA MN, 55391. The company can be reached via phone at 952-974-2222.

This page was last updated on 10/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.